Cambodia's Ministry of Health has approved INDICAID(R) COVID-19 Rapid Antigen 
Test for commercialisation as part of the country's efforts in controlling 
recent spikes of COVID-19 cases in the region. 

Rapid antigen tests like INDICAID(R) have been deployed by the Cambodian 
Government for widescale screening measures in the capital city Phnom Penh and 
neighbouring regions, taking advantage of the tests' short result time and 
convenience to help the Government quickly identify COVID-19 patients and curb 
the disease's spread. These tests have also enabled better containment 
measures, effectively dividing the capital into red, orange, and yellow zones 
depending on case numbers and transmission risks. INDICAID(R) is also available 
in Phnom Penh for retail. 

"We are confident that the accuracy, ease of use and affordability of our test 
kits will position INDICAID(R) to play an important role of the Cambodian 
Government's ongoing screening efforts in the region," says Ricky Chiu, Founder 
and CEO of PHASE Scientific, the official manufacturer of the INDICAID(R) test 
kits. "We welcome the Cambodian Government's decision and look forward to 
bringing our rapid test kits to support its neighbouring countries as well."

According to Chiu, INDICAID(R) is adopted in multiple countries to combat 
COVID-19. In Hong Kong, where PHASE Scientific is headquartered at, INDICAID(R) 
has been endorsed by the Government as a designated product for hospital and 
care home visitation, and is the top selling brand of its kind with over 2 
million kits sold. It has also been widely adopted in hospitals, government and 
private corporations, supermarkets, hotels and schools for regular screening 
both locally and internationally.

The INDICAID(R) COVID-19 Rapid Antigen Test is a CE-marked lateral flow 
immunoassay designed for the qualitative detection of SARS-CoV-2 antigens in 
direct nasal swab samples. With reliable product quality and ease-of-use, 
INDICAID(R) can provide fast results within 20 minutes with no special 
equipment or facilities needed. The test kit's accuracy has been clinically 
validated in the world's largest dual-track clinical trial, where INDICAID(R) 
was tested against PCR in over 9,200 samples and was shown to demonstrate high 
sensitivity and specificity. 

INDICAID(R) is currently available in 33 countries, and in the process of 
obtaining Emergency Use Authorization (EUA) from the US Food & Drug 
Administration (FDA).

SOURCE PHASE Scientific